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Background
Osteopenia and osteoporosis (O) are emerging compli-
cations of HIV infection, especially when treated with
combined antiretroviral therapy (cART). The pathogen-
esis is multifactorial, potentially involving all classes of
anti-HIV drugs, although protease inhibitor (PI) use,
overall HIV and cART duration, and the male sex, seem
related to a significantly greater risk.
Methods
In a preliminary DEXA screening assessing lumbar spine
and femoral head of around 100 out of around 1,000
single-centre patients (p), the frequency of osteopenia-
osteoporosis (based on lumbar T-score) was assessed
around 48%. An increased risk was found in p treated
with protease inhibitors versus p receiving non-nucleo-
side reverse transcriptase inhibitor, or triple nucleos(t)
ide reverse transcriptase inhibitors.
Results
Prospective studies of extensive p samples are needed,
to elucidate the epidemiology, pathogenesis, clinical
issues, and evolution of HIV-associated bone metabo-
lism abnormalities. When planning strategies for their
early diagnosis, prevention, and management, also cost-
effectiveness issues should be taken into consideration,
since no pharmacoeconomic data still exist in this set-
ting. Although severe consequences (pathological frac-
tures, prosthetic implants), are expected to be
proportionally infrequent events, their consequences in
terms of length-intensity of hospitalization, related costs,
and especially consequences on the patient’sq u a l i t yo f
life, are expected to play a remarkable role. Anyway, the
most reliable diagnostic procedure of O (i.e. DEXA
scan), has affordable costs (around Eur 43.40 for a scan
which also offers a body composition assessment), as
well as the first-line drugs for osteopenia, e.g. supple-
mentation with calcium (Eur 6/month), and vitamin D
(Eur 7/month). These costs cannot be compared with
the standards costs of an asymptomatic cART-treated p
(Eur 471 to 874/month), and the immunologic, virolo-
gic, laboratory, and clinical controls made at least quar-
terly in the same p.
Discussion
Like post-menopausal O, also HIV disease should be
investigated from multiple cost-effectiveness points of
view, to establish which p are the early candidates for a
DEXA screening, when this examination is more useful
during HIV disease course-therapy, when the DEXA
scan should be repeated, and when-how to intervene
pharmacologically, in order to prevent serious and
potentially invalidating O-related complications.
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